Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAGON-II in hormone receptor-positive advanced gynecologic cancers
ACTRN12621000639820Phase 2Active, not recruiting
- Sponsor
- The University of Sydney
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of letrozole, alpelisib and ribociclib in endometrial cancer (EC), ovarian cancer, fallopian tube cancer (PFTC) and 4 more (3 arms), sponsored by The University of Sydney. Primary endpoint: Objective response rate. Started Aug 2022; status: active, not recruiting.
02
Drugs
letrozolealpelisibribociclib
03
Conditions
endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Endometrial Sarcoma (ESS)
Beyond the preview
Go deeper on ACTRN12621000639820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000639820.